Global network grid

Unleashing global market access success 

Evidence-generation strategies for expanding life sciences companies 

Life sciences companies face many complexities when venturing into new markets overseas, including expansion within the E.U. and the U.K. From determining the required level of evidence to securing payer and provider coverage, to effectively conveying the value of products, devices, or therapeutics, entering new markets demands careful planning and execution.   

Join Baker Tilly for an informative webinar where our team will discuss how entering into a new market and diversifying your portfolio can position your life sciences company for long-term success.  

Our team of specialists will explore the risks involved and strategies to overcome those challenges to achieve market access success in foreign markets, emphasizing the importance of having a solid evidence-generation strategy. Additionally, we will delve into how leveraging data and understanding the approval process by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) can contribute to your company streamlining commercial success in the U.S. and abroad, including the perspective from the U.K.’s National Institute for Health and Care Education (NICE). 

 Who should attend 

  • C-Suite executives as well as professionals involved in market access, medical affairs, health economics and outcomes research (HEOR), compliance and operations of life sciences companies that operate in multiple countries or are looking to expand into additional markets in the coming years. 


  • Arun Parekkat, MBA, MS, Managing Director, Baker Tilly 


  • David Gregory, MPA, FACHE, Principal, Baker Tilly 
  • Grace Macalino, PhD, MPH, Director, Baker Tilly 
  • Sheela Upadhyaya, Consultant in Rare Diseases Market Access & Evidence Strategies. Chair, International Society for Patient Outcomes Research (ISPOR) Rare Disease Special Interest Group (SIG) and former NICE advisor 

Learning objectives 

  • Define the risks and challenges involved in entering new foreign markets and diversifying a life sciences company's portfolio 
  • Explore strategies to achieve market access success within new markets, with an emphasis on developing a solid evidence-generation strategy 
  • Demonstrate how leveraging data and understanding the approval processes of regulatory agencies like the FDA, EMA, and NICE can contribute to streamlining commercial success for life sciences companies 

There are no prerequisites for this webinar, and advance preparation is not required. There is no cost to attend this webinar.  

A certificate of completion will be emailed to you four to six weeks after the event. 
Level: Basic 
CPE credit: One (1) hour total credit 
Field of study: Specialized Knowledge (SK) 

Host: Stephanie Parker 

For more information regarding administrative policies such as complaint and refund policies, please email [email protected]


Baker Tilly is registered with the National Association of State Boards of Accountancy as a sponsor of continuing professional education on the National Registry of CPE Sponsors. State boards of accountancy have final authority on the acceptance of individual courses for CPE credit. Complaints regarding registered sponsors may be submitted to the National Registry of CPE Sponsors through its website:

Similar events


Shifting supply chain discussions to value chain discussions


AI: Business uses, risks and rewards


Finding results through resiliency and sustainability


Beyond compliance: Optimizing the Three Lines Model